-
National pharmacare by 2020 would cost $9.7 B in public funding but save more in total costs: analysis
A new analysis in CMAJ (Canadian Medical Association Journal) outlines the potential government cost of a national Canadian pharmacare program and sets out approaches to shifting the funding for drugs in Canada to realize billions in savings. -
Trazodone associated with similar risk of falls and major fractures as antipsychotics in seniors with dementia
As physicians attempt to decrease antipsychotic use in seniors with dementia, they need to be aware that trazodone, frequently used as an alternative, is associated with a similar risk of falls and major fractures as atypical antipsychotics, according to new research.
